Melanie Agnes Mariano, NP
Nurse Practitioner · Austell, GANPI 1912677329
Payments from drug & device makers
Across 296 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$738
- Lilly USA, LLC$540
- Amgen$449
- Sanofi-aventis U.S. LLC$446
- Abbott$406
- Insulet Corporation$365
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,63499%
- Other$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 47 | $738 |
| Lilly USA, LLC | 29 | $540 |
| Amgen | 25 | $449 |
| Sanofi-aventis U.S. LLC | 16 | $446 |
| Abbott | 25 | $406 |
| Insulet Corporation | 18 | $365 |
| Bayer | 16 | $314 |
| Mannkind Corporation | 9 | $212 |
| Boehringer Ingelheim | 11 | $208 |
| AbbVie | 11 | $158 |
| Sequel Med Tech, LLC | 3 | $152 |
| Xeris Pharmaceuticals, Inc. | 7 | $147 |
| Dexcom, Inc. | 7 | $143 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $120 |
| AstraZeneca(2 entities) | 7 | $116 |
| Cequr Corporation | 2 | $114 |
| Novartis | 5 | $114 |
| Recordati_rare_diseases_inc. | 4 | $91 |
| GSK | 6 | $89 |
| Ascendis Pharma Endocrinology Inc | 4 | $85 |
| Tandem Diabetes Care, Inc. | 4 | $82 |
| Esperion Therapeutics, Inc. | 4 | $78 |
| Merck | 3 | $62 |
| BETA Bionics, Inc. | 3 | $54 |
| IBSA Pharma Inc. | 3 | $53 |
| Sumitomo Pharma America, Inc. | 4 | $51 |
| Corcept Therapeutics | 2 | $45 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Shield Therapeutics Inc | 2 | $35 |
| Medtronic | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Amphastar Pharmaceuticals, Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Pfizer | 1 | $12 |
| Eisai Inc. | 1 | $12 |
How this compares
$5,664 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 170 | $264,965 |
| JardianceEmpagliflozin | 151 | $196,930 |
| MounjaroTirzepatide | 115 | $159,986 |
| FarxigaDapagliflozin Propanediol | 59 | $66,258 |
| TrulicityDulaglutide | 43 | $65,887 |
| RybelsusSemaglutide | 27 | $43,697 |
| JanuviaSitagliptin Phosphate | 33 | $38,226 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 21 | $35,040 |
| TradjentaLinagliptin | 32 | $30,144 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $30,012 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $20,322 |
| Novolog FlexpenInsulin Aspart | 34 | $15,600 |
| Humalog Kwikpen U-100Insulin Lispro | 22 | $15,460 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $15,072 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $11,943 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $738 | $308,663197 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $540 | $233,113186 claims |
| Boehringer IngelheimJardiance, Tradjenta | $208 | $227,074183 claims |
| AstraZenecaFarxiga | $116 | $66,25859 claims |
| MerckJanuvia | $62 | $38,22633 claims |
| Sanofi-aventis U.S. LLCLantus | $446 | $6,58614 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $23 | $3,660358 claims |
| AbbVieSynthroid | $158 | $1,88528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Other nurse practitioner in Austell
- Crystal LogsdonSavannah$566K
- Victor CzerkasijDalton$505K
- Kennon Mc CollumStockbridge$364K
- Pamela AllenRome$270K
- Tajuana BradleyJohns Creek$256K
- Janice McAlisterAtlanta$241K
- Jessica AdkinsSavannah$226K
- Laura ElledgeAtlanta$177K
- Afsha HussainiKennesaw$122K
- Elizabeth TyeAlbany$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.